Full-Time

Associate Director/Principal Scientist

Immunology Discovery Research

Posted on 8/16/2024

Generation Bio

Generation Bio

51-200 employees

Develops durable genetic treatments for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD in immunology or related field with minimum of 6 years relevant experience required
  • Experience across multiple fields of immunology, such as deep knowledge of diverse cell types and disease areas required
  • Track record of contributing to a cross-functional project team and enabling achievement of milestones as a leader and collaborative team player
  • Deep understanding of flow cytometry and immunophenotyping with complex flow panels
  • Previous experience designing pharmacology studies required
  • Curious, detail oriented, eager to tackle hard problems, and ability to communicate complex issues effectively
Responsibilities
  • Conceptualize experimental path to evaluate novel target biology and design PoC in vitro experiments
  • Contribute to the strategic thinking of novel target concepts
  • Design and execute in vivo pharmacology studies in WT and disease models
  • Analyze and report data, synthesizing key results and crafting strategic path forward
  • CRO management in collaboration with preclinical operations group
  • Project leadership, responsible for balancing resources and executing on deliverables, with the ability to influence, design, and scope out new project initiatives in a matrixed team
  • Mentor direct reports and other scientists within the group

Generation Bio focuses on developing genetic treatments for both rare and common diseases. Their main product is based on a non-viral genetic medicine platform that includes iqDNA, which is designed to be immune-quiet, and ctLNP, a delivery system that targets specific cells. This platform allows for the delivery of large amounts of genetic material to particular tissues, aiming to provide long-lasting effects from a single treatment. They use a unique manufacturing process called rapid enzymatic synthesis (RES) that enables them to produce these treatments at scale, potentially reaching hundreds of millions of doses. Unlike many competitors, Generation Bio's approach allows for redosing and adjusting treatment levels based on patient needs. The company's goal is to make genetic medicine more accessible and effective for a wider range of patients.

Company Stage

IPO

Total Funding

$252.9M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-6%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic reorganization extends cash runway into 2H 2027, supporting long-term R&D.
  • Partnership with Moderna highlights demand for non-viral delivery systems.
  • Focus on both rare and prevalent diseases expands market potential significantly.

What critics are saying

  • 40% workforce reduction may impact innovation and project execution.
  • Lease termination could indicate potential legal or financial disputes.
  • Financial constraints might limit future R&D investments despite extended cash runway.

What makes Generation Bio unique

  • Generation Bio's iqDNA evades immune detection, unlike traditional viral vectors.
  • Their ctLNP system offers targeted delivery to specific tissues and cell types.
  • RES manufacturing process is scalable, supporting large-scale production of genetic medicines.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE